XML 85 R21.htm IDEA: XBRL DOCUMENT
v3.20.1

Stock-Based Compensation | 3 Months Ended
--- | ---
Mar. 31, 2020
Share-based Payment Arrangement [Abstract] |
Stock-Based Compensation | Stock-Based Compensation Stock-based compensation expense for each employee and director is presented in the same statement of operations caption as their cash compensation. Stock-based compensation expense by statement of operations caption and the related income tax benefit were as follows:
| Three Months Ended March 31,
(In thousands) | 2020 |  | 2019
Cost of sales | $ | 74 |  |  | $ | 28 |
Research and development expenses | 236 |  |  | 220 |
Selling, general and administrative expenses: |  |  |
Employees | 1,583 |  |  | 1,424 |
Outside directors | 410 |  |  | 246 |
Total employee and director stock-based compensation expense | $ | 2,303 |  |  | $ | 1,918 |
Income tax benefit | $ | 506 |  |  | $ | 399 |
Stock Options Stock option activity was as follows:
| Number of Options (in 000's) |  | Weighted-Average Exercise Price |  | Weighted-Average Remaining Contractual Term (in years) |  | Aggregate Intrinsic Value (in 000's)
Outstanding at December 31, 2019 | 745 |  |  | $ | 41.73 |  |  |  |  |
Granted | 109 |  |  | 46.17 |  |  |  |  |
Exercised | — |  |  | — |  |  |  |  | $ | — |
Forfeited/canceled/expired | — |  |  | — |  |  |  |  |
Outstanding at March 31, 2020 (1) | 854 |  |  | $ | 42.29 |  |  | 4.13 |  | $ | 4,070 |
Vested and expected to vest at March 31, 2020 (1) | 854 |  |  | $ | 42.29 |  |  | 4.13 |  | $ | 4,070 |
Exercisable at March 31, 2020 (1) | 592 |  |  | $ | 43.66 |  |  | 3.10 |  | $ | 2,933 |
(1) | The aggregate intrinsic value represents the total pre-tax value (the difference between our closing stock price on the last trading day of the first quarter of 2020 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had they all exercised their options on March 31, 2020. This amount will change based on the fair market value of our stock.
The assumptions we utilized in the Black-Scholes option pricing model and the resulting weighted average fair value of stock option grants were the following:
| Three Months Ended March 31,
| 2020 |  | 2019
Weighted average fair value of grants | $ | 17.70 |  |  | $ | 10.28 |
Risk-free interest rate | 1.44 | % |  | 2.49 | %
Expected volatility | 43.95 | % |  | 41.64 | %
Expected life in years | 4.59 |  |  | 4.54 |
As of March 31, 2020, we expect to recognize $3.6 million of total unrecognized pre-tax stock-based compensation expense related to non-vested stock options over a remaining weighted-average life of 2.3 years. Restricted Stock Non-vested restricted stock award activity was as follows:
| Shares (in 000's) |  | Weighted-Average Grant Date Fair Value
Non-vested at December 31, 2019 | 310 |  |  | $ | 34.99 |
Granted | 198 |  |  | 35.11 |
Vested | (124 | ) |  | 38.17 |
Forfeited | (1 | ) |  | 36.06 |
Non-vested at March 31, 2020 | 383 |  |  | $ | 34.02 |
As of March 31, 2020, we expect to recognize $12.4 million of total unrecognized pre-tax stock-based compensation expense related to non-vested restricted stock awards over a weighted-average life of 2.3 years.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration